UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000041015 |
|---|---|
| Receipt number | R000046793 |
| Scientific Title | Onivyde I.V. infusion 43 mg General Drug Use-Results Survey (Unresectable pancreatic cancer after disease progression following cancer chemotherapy) |
| Date of disclosure of the study information | 2020/07/07 |
| Last modified on | 2024/01/19 10:45:50 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Onivyde I.V. infusion 43 mg General Drug Use-Results Survey (Unresectable pancreatic cancer after disease progression following cancer chemotherapy)
Acronym
Onivyde General Drug Use-Results Survey (Pancreatic cancer)
Scientific Title
Onivyde I.V. infusion 43 mg General Drug Use-Results Survey (Unresectable pancreatic cancer after disease progression following cancer chemotherapy)
Scientific Title:Acronym
Onivyde General Drug Use-Results Survey (Pancreatic cancer)
Region
| Japan |
Condition
Condition
Pancreatic cancer
Classification by specialty
| Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate Safety and Effectiveness of Onivyde I.V. Infusion 43 mg in patients with Unresectable Pancreatic Cancer after disease progression following cancer chemotherapy in clinical practice and to detect issues expeditiously.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Overall incidence of each ADRs and AEs (Safety Specifications of the Survey related)
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients who are administered Onivyde for the first time to Unresectable pancreatic cancer after disease progression following cancer chemotherapy per standard clinical practice and per prescribing information. In addition, patients who are given consent to participation in the survey.
Key exclusion criteria
No given consent to participation in the survey.
Target sample size
300
Research contact person
Name of lead principal investigator
| 1st name | Satoshi |
| Middle name | |
| Last name | KAMEYAMA |
Organization
NIHON SERVIER CO., LTD.
Division name
MEDICAL AFFAIRS
Zip code
113-0033
Address
Hongo MK Bldg., 1-28-34, Hongo, Bunkyo-ku, Tokyo, Japan
TEL
07024933214
satoshi.kameyama@servier.com
Public contact
Name of contact person
| 1st name | Satoshi |
| Middle name | |
| Last name | KAMEYAMA |
Organization
NIHON SERVIER CO., LTD.
Division name
MEDICAL AFFAIRS
Zip code
113-0033
Address
Hongo MK Bldg., 1-28-34, Hongo, Bunkyo-ku, Tokyo, Japan
TEL
07024933214
Homepage URL
satoshi.kameyama@servier.com
Sponsor or person
Institute
NIHON SERVIER CO., LTD.
Institute
Department
Personal name
Funding Source
Organization
NIHON SERVIER CO., LTD.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
NIHON SERVIER CO., LTD.
Address
Hongo MK Bldg., 1-28-34, Hongo, Bunkyo-ku, Tokyo, Japan
Tel
07024933214
satoshi.kameyama@servier.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 07 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
326
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2020 | Year | 04 | Month | 30 | Day |
Date of IRB
| 2020 | Year | 04 | Month | 30 | Day |
Anticipated trial start date
| 2020 | Year | 06 | Month | 01 | Day |
Last follow-up date
| 2023 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
The survey will be conducted to be followed GPSP Ministerial Ordinance, relevant regulations and Operating Procedures to ensure the quality of the survey.
Management information
Registered date
| 2020 | Year | 07 | Month | 06 | Day |
Last modified on
| 2024 | Year | 01 | Month | 19 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046793
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
